1. A Thirteen-Gene Expression Signature Predicts Survival of Patients with Pancreatic Cancer and Identifies New Genes of Interest
- Author
-
Todd W. Bauer, J. Thomas Parsons, Jason A. Papin, James M. Lindberg, Sara J. Adair, Jae K. Lee, Wenjun Xin, Timothy E. Newhook, and Edik M. Blais
- Subjects
Oncology ,medicine.medical_specialty ,Pancreatic ductal adenocarcinoma ,endocrine system diseases ,Genetic Causes of Cancer ,lcsh:Medicine ,Adenocarcinoma ,Bioinformatics ,Metastasis ,Pancreatic Cancer ,Breast cancer ,Pancreatic cancer ,Internal medicine ,Gene expression ,Gastrointestinal Tumors ,medicine ,Medicine and Health Sciences ,Humans ,lcsh:Science ,Gene ,Staging system ,Multidisciplinary ,business.industry ,Cancer Risk Factors ,Gene Expression Profiling ,lcsh:R ,Cancers and Neoplasms ,Reproducibility of Results ,medicine.disease ,Prognosis ,Survival Analysis ,digestive system diseases ,Up-Regulation ,Gene Expression Regulation, Neoplastic ,Pancreatic Neoplasms ,lcsh:Q ,Treatment decision making ,Lymph Nodes ,business ,Research Article ,Carcinoma, Pancreatic Ductal ,Genes, Neoplasm ,Signal Transduction - Abstract
Background Currently, prognostication for pancreatic ductal adenocarcinoma (PDAC) is based upon a coarse clinical staging system. Thus, more accurate prognostic tests are needed for PDAC patients to aid treatment decisions. Methods and Findings Affymetrix gene expression profiling was carried out on 15 human PDAC tumors and from the data we identified a 13-gene expression signature (risk score) that correlated with patient survival. The gene expression risk score was then independently validated using published gene expression data and survival data for an additional 101 patients with pancreatic cancer. Patients with high-risk scores had significantly higher risk of death compared to patients with low-risk scores (HR 2.27, p = 0.002). When the 13-gene score was combined with lymph node status the risk-score further discriminated the length of patient survival time (p
- Published
- 2014